{"id":"biib104","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"BIIB104 targets LRRK2, a kinase implicated in Parkinson's disease pathogenesis. By inhibiting LRRK2 activity, the drug aims to reduce the accumulation of alpha-synuclein and other pathological proteins that contribute to neurodegeneration. This mechanism is intended to slow or halt disease progression in LRRK2-associated Parkinson's disease.","oneSentence":"BIIB104 is a selective inhibitor of leucine-rich repeat kinase 2 (LRRK2) that reduces pathological protein aggregation in neuronal cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:23:58.612Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"LRRK2-associated Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT03745820","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2018-11-15","conditions":"Cognitive Impairment Associated With Schizophrenia","enrollment":195},{"nctId":"NCT05148481","phase":"PHASE1","title":"A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2021-11-23","conditions":"Healthy Volunteer","enrollment":31},{"nctId":"NCT05152485","phase":"PHASE1","title":"A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2021-12-15","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT04079101","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2019-10-02","conditions":"Healthy Volunteers","enrollment":31},{"nctId":"NCT04068532","phase":"PHASE1","title":"A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2019-11-15","conditions":"Healthy Volunteers","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PF-04958242"],"phase":"phase_2","status":"active","brandName":"BIIB104","genericName":"BIIB104","companyName":"Biogen","companyId":"biogen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BIIB104 is a small molecule that acts as a positive allosteric modulator of the glutamate receptor ionotropic AMPA. It is being studied in a Phase 2 clinical trial for the treatment of cognitive impairment associated with schizophrenia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}